
Site burden is now measured through satisfaction surveys, in-the-moment check-ins, and adoption patterns, but each method catches a different moment, and the gaps between them decide whether teams can act before burden becomes risk.
Harbour BioMed and Pharmaceutical Product Development, LLC have announced that HBM will use the services of PPD’s Biotech to develop innovative therapeutics in the areas of oncology and immunology.
To learn more, click






